

Genome Report

## Whole-genome sequence of bioactive streptomycete derived from mangrove forest in Malaysia, *Streptomyces* sp. MUSC 14

Hooi-Leng Ser<sup>1</sup>, Loh Teng Hern Tan<sup>1,2</sup>, Wen-Si Tan<sup>3,4</sup>, Wai-Fong Yin<sup>4</sup>, Kok-Gan Chan<sup>4,5\*</sup>

### Article History

Received: 8 February 2021;

Received in Revised Form:  
10 April 2021;

Accepted: 12 April 2021;

Available Online: 22 April  
2021

<sup>1</sup>Novel Bacteria and Drug Discovery (NBDD) Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia; ser.hooileng@monash.edu (H-LS)

<sup>2</sup>Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Johor Bahru 80100, Malaysia; loh.teng.hern@monash.edu (LT-HT)

<sup>3</sup>Illumina Singapore Pte Ltd, Woodlands Industrial Park E1, Singapore; tmarilyn36@gmail.com (W-ST)

<sup>4</sup>Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia; yinwaifong@yahoo.com (W-FY)

<sup>5</sup>Vice Chancellor Office, Jiangsu University, Zhenjiang 212013, PR China

\*Corresponding author: Kok-Gan Chan, kokgan@um.edu.my (K-GC)

**Abstract:** The contribution of streptomycetes to human health is undeniably important and significant, given that these filamentous microbes can produce interesting compounds that can be used to cure deadly infections and even cancer. Isolated from the east coast of Peninsular Malaysia, *Streptomyces* sp. MUSC 14 has shown significant antioxidant capacity. The current study explores the genomic potential of MUSC 14 via a genome mining approach. The genome size of MUSC 14 is 10,274,825 bp with G + C content of 71.3 %. AntiSMASH analysis revealed a total of nine biosynthetic gene clusters (with more than 80 % similarities to known gene clusters). This information serves as an important foundation for subsequent studies, particularly the purification and isolation of bioactive compounds by genetic manipulation techniques.

**Keywords:** *Streptomyces*, antioxidant, mangrove, genome, MUSC 14, actinobacteria

---

### 1. Short Introduction

Gifted with the ability to form spores, streptomycetes are ubiquitous in nature and produce a diverse array of secondary metabolites that can be exploited for the benefit of humanity<sup>[1-16]</sup>. One of the significant breakthroughs in streptomycetes research is the discovery of streptomycin (from the soil bacterium, *Streptomyces griseus*) by Professor

Waksman and his team – which subsequently led him to the Nobel Award in Medicine later in 1960<sup>[13, 17-21]</sup>. As a matter of fact, the continuous search for pharmaceutically important compounds led to another (one half jointly) Nobel Prize in Physiology or Medicine in 2015 awarded to Professor William C. Campbell and Professor Satoshi Ōmura for the discovery of avermectin, which was isolated from a soil streptomycete, *Streptomyces avermitilis*<sup>[22-27]</sup>. The search for bioactive compounds from this prolific genus seems like a never-ending journey, with researchers now hunt for them in unique environments such as hot springs, volcanic soils, deserts, deep-sea, and the mangrove forest<sup>[28-42]</sup>. The hypothesis behind searching these special habitats is that microbes may come up with adaptation strategies to ensure their survival in the harsh condition like drastic temperature changes, salinity, and oxygen availability, which in turn may lead to the production of interesting compounds and drive the emergence of a novel bacterium<sup>[43-50]</sup>. *Streptomyces* sp. MUSC 14 was isolated from the mangrove forest on the west coast of Peninsular Malaysia during a screening program for bioactive actinobacteria<sup>[4, 51, 52]</sup>. A thorough investigation conducted on the strain has reflected the antioxidant potential of MUSC 14, attributed to its production of bioactive secondary metabolites, including pyrrolopyrazines and fatty acid esters<sup>[51, 53-55]</sup>. The current study aims to obtain the genome sequence of *Streptomyces* sp. MUSC 14 before exploring the genomic potential of this strain.

## 2. Data description


The whole genomic DNA extraction of MUSC 14 was carried out using Masterpure™ DNA purification kit (Epicentre, Illumina Inc., Madison, WI, USA), preceding RNase treatment (Qiagen, USA)<sup>[56-58]</sup>. Subsequently, the DNA library was constructed with Nextera™ DNA Sample Preparation kit (Nextera, USA). The library quality was evaluated by Bioanalyzer 2100 high sensitivity DNA kit (Agilent Technologies, Palo Alto, CA)<sup>[59, 60]</sup>. Paired-end sequencing was performed on the Illumina MiSeq platform with MiSeq Reagent Kit 2 (2 × 250 bp; Illumina Inc., Madison, WI, USA)<sup>[16, 61, 62]</sup>. Post-trimming step, *de novo* assembly of the paired-end reads on CLC Genomics Workbench version 7 (CLC bio, Denmark) resulted in 174 contigs and an N<sub>50</sub> contig size of 162,032 bp. The genome size of MUSC 14 is 10,274,825 bp, with an average coverage of 211.0-fold and G + C content of 71.3% (**Table 1**). The genome sequence of MUSC 14 has been deposited at DDBJ/EMBL/GenBank under accession of MLYN00000000. The version described in this paper is the first version.

Following genome assembly, MUSC 14 genome was annotated on Rapid Annotation using Subsystem Technology (RAST) and NCBI Prokaryotic Genome Annotation Pipeline (PGAP)<sup>[63-66]</sup>. Gene prediction was performed using Prodigal (version 2.6)<sup>[67]</sup>, while ribosomal RNA (rRNA) and transfer RNA (tRNA) were predicted using RNAmmer<sup>[68]</sup> and tRNAscan SE version 1.21<sup>[69]</sup>, respectively. The whole genome of MUSC 14 consists of 8,799 protein-coding genes and 81 RNA genes (tRNA: 74, rRNA:4).

**Table 1.** General genomic features of *Streptomyces* sp. MUSC 14.

Properties	<i>Streptomyces</i> sp. MUSC 14
Genome size (bp)	10,274,825
Contigs	174
Contigs N <sub>50</sub> (bp)	162,032
G + C content %	71.3

Genome coverage	211.0
Protein coding genes	8,799
tRNA	74
rRNA (5S, 16S, 23S)	4 (2, 1, 1)



**Figure 1.** Annotation of MUSC 14<sup>T</sup> genome using Rapid Annotation using Subsystem Technology (RAST).

The annotation on RAST showed that most of the protein-coding genes were involved in metabolic processes, with the highest number of genes involved in carbohydrates metabolism (7.60%) (**Figure 1**). Subsequent analysis to investigate the genomic potential of MUSC 14 on antibiotics & Secondary Metabolite Analysis SHell (antiSMASH)<sup>[70-74]</sup> revealed a total of nine biosynthetic gene clusters displaying more than 80% similarities to known biosynthetic gene clusters. Besides detecting the gene cluster responsible for the production of the earthy odorant geosmin (100% gene similarities), there is one biosynthetic gene cluster related to nonribosomal peptides production and reflects 100% gene similarities with thioholgamide A/thioholgamide B biosynthesis. Thioholgamide A and B were initially isolated from a mangrove-derived streptomycete, *Streptomyces malaysiense* MUSC 136<sup>T</sup>, and possess cytotoxic activities against cancer cell lines<sup>[75, 76]</sup>. Recently, a research group in Germany has published an article studying the mechanisms involved behind the cytotoxic and anti-proliferative activities of thioholgamide A<sup>[75, 77]</sup>. The team showed that thioholgamide A induces apoptosis via caspase 3 and PARP cleavage (at concentrations comparable to staurosporine)<sup>[77]</sup>. Furthermore, it appears that thioholgamide A inhibits oxidative phosphorylation in tumor cells without displaying much toxicity towards non-tumorigenic cells and zebrafish embryos, thus making the compound an appealing candidate that to be developed as anti-cancer therapeutics. Harnessing the genomic potential of microbes, including *Streptomyces* sp. is indeed one way forward in drug discovery<sup>[78-80]</sup>. Combined with the conventional methods, including optimization of fermentation media and improvement in extraction processes, the activation of biosynthetic gene clusters via heterologous expression or introduction of promoters in the native host can potentially yield bioactive compound(s) of interest in high purity and quantity, allowing its large-scale production for pharmaceutical use<sup>[81-85]</sup>.

**Author Contributions:** HLS, LTHT, and WST carried out the experiments and analyzed the data. WFY and KGC provided vital guidance, technical support, and proofreading for the work. All authors approved the final draft.

**Funding:** This work was supported by the University of Malaya for High Impact Research Grant (UM-MOHE HIR Nature Microbiome Grant No. H-50001-A000027 and No. A000001-5001) and PPP Grant (PG090-2015B) awarded to K-GC.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Law JW-F, Letchumanan V, Tan LT-H, *et al.*, The rising of “modern actinobacteria” era. *Prog Microbes Mol Biol* 2020; 3(1).
2. Chang T-L, Huang T-W, Wang Y-X, *et al.*, An actinobacterial isolate, *Streptomyces* sp. YX44, produces broad-spectrum antibiotics that strongly inhibit *Staphylococcus aureus*. *Microorganisms* 2021; 9(3): 630.
3. Law JW-F, Pusparajah P, Ab Mutalib N-S, *et al.*, A review on mangrove actinobacterial diversity: the roles of *Streptomyces* and novel species discovery. *Prog Microbes Mol Biol* 2019; 2(1).
4. Lee L-H, Zainal N, Azman A-S, *et al.*, Diversity and antimicrobial activities of actinobacteria isolated from tropical mangrove sediments in Malaysia. *Sci World J* 2014; 2014.
5. Rizo-Liendo A, Sifaoui I, Cartuche L, *et al.*, Evaluation of indolocarbazoles from *Streptomyces sanyensis* as a novel source of therapeutic agents against the brain-eating amoeba *Naegleria fowleri*. *Microorganisms* 2020; 8(5): 789.
6. Kemung HM, Tan LT-H, Khan TM, *et al.*, *Streptomyces* as a prominent resource of future anti-MRSA drugs. *Front Microbiol* 2018; 9: 2221.
7. Ser H-L, Chan K-G, Tan W-S, *et al.*, Complete genome of mangrove-derived anti-MRSA streptomycete, *Streptomyces pluripotens* MUSC 135<sup>T</sup>. *Prog Microbes Mol Biol* 2018; 1(1).
8. Terra L, Dyson P, Ratcliffe N, *et al.*, Biotechnological potential of *Streptomyces* siderophores as new antibiotics. *Curr Med Chem* 2020.
9. Tan LT-H, Lee L-H, and Goh B-H, Critical review of fermentation and extraction of anti-Vibrio compounds from *Streptomyces*. *Prog Microbes Mol Biol* 2020; 3(1).
10. Lee SR, Song JH, Song J-H, *et al.*, Chemical identification of isoflavonoids from a termite-associated *Streptomyces* sp. RB1 and their neuroprotective effects in murine hippocampal HT22 cell line. *Int J Mol Sci* 2018; 19(9): 2640.
11. Lee L-H, Goh B-H, and Chan K-G, Actinobacteria: Prolific producers of bioactive metabolites. *Front Microbiol* 2020; 11.
12. Tan LTH, Mahendra CK, Yow YY, *et al.*, *Streptomyces* sp. MUM273b: A mangrove-derived potential source for antioxidant and UVB radiation protectants. *MicrobiologyOpen* 2019; 8(10): e859.
13. Quinn GA, Banat AM, Abdelhameed AM, *et al.*, *Streptomyces* from traditional medicine: sources of new innovations in antibiotic discovery. *J Med Microbiol* 2020; 69(8): 1040.
14. Law JW-F, Law LN-S, Letchumanan V, *et al.*, Anticancer drug discovery from microbial sources: The unique mangrove streptomycetes. *Molecules* 2020; 25(22): 5365.
15. Ser H-L, Tan LT-H, Law JW-F, *et al.*, Focused review: cytotoxic and antioxidant potentials of mangrove-derived *Streptomyces*. *Front Microbiol* 2017; 8: 2065.
16. Ser H-L, Tan W-S, Ab Mutalib N-S, *et al.*, Genome sequence of *Streptomyces mangrovisoli* MUSC 149<sup>T</sup> isolated from intertidal sediments. *Braz J Microbiol* 2018; 49(1): 13-15.

17. Schatz A, Bugle E, and Waksman SA, Streptomycin, a substance exhibiting antibiotic activity against Gram-Positive and Gram-Negative Bacteria. *Proc Soc Exp Biol Med* 1944; 55(1): 66-69.
18. Waksman SA, Streptomycin: background, isolation, properties, and utilization. *Science* 1953; 118(3062): 259-266.
19. Waksman SA, Reilly HC, and Harris DA, *Streptomyces griseus* (Krainsky) Waksman and Henrici. *J Bacteriol* 1948; 56(3): 259.
20. Waksman SA, Reilly HC, and Johnstone DB, Isolation of streptomycin-producing strains of *Streptomyces griseus*. *J Bacteriol* 1946; 52(3): 393.
21. Waksman SA, Schatz A, and Reilly HC, Metabolism and the chemical nature of *Streptomyces griseus*. *J Bacteriol* 1946; 51(6): 753.
22. Ikeda H, Kotaki H, and Omura S, Genetic studies of avermectin biosynthesis in *Streptomyces avermitilis*. *J Bacteriol* 1987; 169(12): 5615-5621.
23. Burg RW, Miller BM, Baker EE, *et al.*, Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. *Antimicrob Agents Chemother* 1979; 15(3): 361-7.
24. Van Voorhis WC, van Huijsduijnen RH, and Wells TN, Profile of William C. Campbell, Satoshi Ōmura, and Youyou Tu, 2015 Nobel Laureates in Physiology or Medicine. *Proc Natl Acad Sci* 2015; 112(52): 15773-15776.
25. Ikeda H, Ishikawa J, Hanamoto A, *et al.*, Complete genome sequence and comparative analysis of the industrial microorganism *Streptomyces avermitilis*. *Nat Biotechnol* 2003; 21(5): 526-531.
26. Kim SB and Goodfellow M, *Streptomyces avermitilis* sp. nov., nom. rev., a taxonomic home for the avermectin-producing streptomycetes. *Int J Syst Evol Microbiol* 2002; 52(6): 2011-2014.
27. Egerton J, Ostlind D, Blair L, *et al.*, Avermectins, new family of potent anthelmintic agents: efficacy of the B1a component. *Antimicrob Agents Chemother* 1979; 15(3): 372-378.
28. Sivalingam P, Hong K, Pote J, *et al.*, Extreme environment *Streptomyces*: potential sources for new antibacterial and anticancer drug leads? *Int J Microbiol* 2019; 2019.
29. Sivakala KK, Gutiérrez-García K, Arul Jose P, *et al.*, Desert environments facilitate unique evolution of biosynthetic potential in *Streptomyces*. *Molecules* 2021; 26(3): 588.
30. Wang P, Wang D, Zhang R, *et al.*, Novel macrolactams from a deep-sea-derived *Streptomyces* species. *Mar Drugs* 2021; 19(1): 13.
31. Braña AF, Fiedler H-P, Nava H, *et al.*, Two *Streptomyces* species producing antibiotic, antitumor, and anti-inflammatory compounds are widespread among intertidal macroalgae and deep-sea coral reef invertebrates from the central Cantabrian Sea. *Microb Ecol* 2015; 69(3): 512-524.
32. Amin A, Ahmed I, Khalid N, *et al.*, *Streptomyces caldifontis* sp. nov., isolated from a hot water spring of Tatta Pani, Kotli, Pakistan. *Antonie Van Leeuwenhoek* 2017; 110(1): 77-86.
33. Naragani K, Mangamuri U, Muvva V, *et al.*, Antimicrobial potential of *Streptomyces cheonanensis* VUK-a from mangrove origin. *Int. J. Pharm. Pharm. Sci* 2016; 8: 53-57.
34. Karim MRU, In Y, Zhou T, *et al.*, Nyuzenamides A and B: Bicyclic peptides with antifungal and cytotoxic activity from a marine-derived *Streptomyces* sp. *Organic Letters* 2021.
35. Kim MC, Cullum R, Hebshy A, *et al.*, Mersaquinone, a new tetracene derivative from the marine-derived *Streptomyces* sp. EG1 exhibiting activity against methicillin-resistant *Staphylococcus aureus* (MRSA). *Antibiotics* 2020; 9(5): 252.
36. Masand M, Sivakala KK, Menghani E, *et al.*, Biosynthetic potential of bioactive streptomycetes isolated from arid region of the Thar desert, Rajasthan (India). *Front Microbiol* 2018; 9: 687.

37. Hamed M, Abdrabo M, and Fahmy N, Distribution and characterization of actinomycetes in mangrove habitats (Red Sea, Egypt) with special emphasis on *Streptomyces mutabilis* M3MT483919. J Pure Appl Microbiol 2021; 15(1).
38. Risdian C, Landwehr W, Rohde M, *et al.*, *Streptomyces bathyalis* sp. nov., an actinobacterium isolated from the sponge in a deep sea. Antonie Van Leeuwenhoek 2021; 114(4): 425-435.
39. Zhu Q, Cheng W, Song Y, *et al.*, Complete genome sequence of the deep South China Sea-derived *Streptomyces niveus* SCSIO 3406, the producer of cytotoxic and antibacterial marfuraquinocins. PLoS One 2021; 16(3): e0248404.
40. Goel N, Fatima SW, Kumar S, *et al.*, Antimicrobial resistance in biofilms: Exploring marine actinobacteria as a potential source of antibiotics and biofilm inhibitors. Biotechnology Reports 2021: e00613.
41. Jia F, Liu C, Zhao J, *et al.*, *Streptomyces vulcanius* sp. nov., a novel actinomycete isolated from volcanic sediment. Antonie Van Leeuwenhoek 2015; 107(1): 15-21.
42. Bae M, Kim H, Park S, *et al.*, Discovery of new bioactive secondary metabolites produced by *Streptomyces* strains derived from volcanic islands. Planta Med 2016; 82(S 01): P676.
43. Parrilli E, Tedesco P, Fondi M, *et al.*, The art of adapting to extreme environments: the model system *Pseudoalteromonas*. Physics of Life Reviews 2019.
44. Tan LT-H, Chan K-G, Khan TM, *et al.*, *Streptomyces* sp. MUM212 as a source of antioxidants with radical scavenging and metal chelating properties. Front Pharmacol 2017; 8: 276.
45. Pettit RK, Culturability and secondary metabolite diversity of extreme microbes: expanding contribution of deep sea and deep-sea vent microbes to natural product discovery. Marine Biotechnology 2011; 13(1): 1-11.
46. Lee L-H, Zainal N, Azman A-S, *et al.*, *Mumia flava* gen. nov., sp. nov., an actinobacterium of the family *Nocardioideae*. Int J Syst Evol Microbiol 2014; 64(5): 1461-1467.
47. Law JW-F, Ser H-L, Duangjai A, *et al.*, *Streptomyces colonosnans* sp. nov., a novel actinobacterium isolated from Malaysia mangrove soil exhibiting antioxidative activity and cytotoxic potential against human colon cancer cell lines. Front Microbiol 2017; 8: 877.
48. Ser H-L, Yin W-F, Chan K-G, *et al.*, Antioxidant and cytotoxic potentials of *Streptomyces gilvigriseus* MUSC 26<sup>T</sup> isolated from mangrove soil in Malaysia. Prog Microbes Mol Biol 2018; 1(1).
49. DasSarma S, Extreme microbes: salt-loving microorganisms are helping biologists understand the unifying features of life and molecular secrets of survival under extreme conditions. Am Sci 2007; 95(3): 224-232.
50. Sayed AM, Hassan MH, Alhadrami HA, *et al.*, Extreme environments: microbiology leading to specialized metabolites. J Appl Microbiol 2020; 128(3): 630-657.
51. Kemung HM, Tan LT-H, Chan K-G, *et al.*, Antioxidant activities of *Streptomyces* sp. strain MUSC 14 from mangrove forest soil in Malaysia. BioMed Res Int 2020; 2020: 6402607.
52. Kemung HM, Tan LT-H, Chan K-G, *et al.*, *Streptomyces* sp. strain MUSC 5 from mangrove forest in Malaysia: Identification, antioxidant potential and chemical profiling of its methanolic extract. Prog Microbes Mol Biol 2020; 3(1).
53. Kumar S, Kumar N, Roy P, *et al.*, Synthesis, anti-inflammatory, and antiproliferative activity evaluation of isoindole, pyrrolopyrazine, benzimidazoisoindole, and benzimidazopyrrolopyrazine derivatives. Mol Divers 2013; 17(4): 753-766.
54. Kim J, Park M, Choi J, *et al.*, Design, synthesis, and biological evaluation of novel pyrrolo [1, 2-a] pyrazine derivatives. Bioorg Med Chem Lett 2019; 29(11): 1350-1356.

55. Seo Y, Lee JH, Park S-h, *et al.*, Expansion of chemical space based on a pyrrolo [1, 2-a] pyrazine core: Synthesis and its anticancer activity in prostate cancer and breast cancer cells. *Eur J Med Chem* 2020; 188: 111988.
56. Ser H-L, Tan W-S, Yin W-F, *et al.*, Whole-genome sequence of a novel, mangrove-derived streptomycete, *Streptomyces malaysiense* strain MUSC 136<sup>T</sup>. *Prog Drug Discov Biomed Sci* 2020; 3(1).
57. Ser H-L, Ab Mutalib N-S, Yin W-F, *et al.*, Genome sequence of *Streptomyces antioxidans* MUSC 164<sup>T</sup> isolated from mangrove forest. *Prog Microbes Mol Biol* 2018; 1(1).
58. Ser H-L, Tan W-S, Mutalib N-SA, *et al.*, Genome sequence of *Streptomyces gilvigriseus* MUSC 26<sup>T</sup> isolated from mangrove forest. *Braz J Microbiol* 2018; 49(2): 207-209.
59. Ser H-L, Tan W-S, Cheng H-J, *et al.*, Draft genome of starch-degrading actinobacterium, *Microbacterium mangrovi* MUSC 115<sup>T</sup> isolated from intertidal sediments. *Prog Drug Discov Biomed Sci* 2018; 1(1).
60. Ser H-L, Yin W-F, Chan K-G, *et al.*, Genome sequence of *Novosphingobium malaysiense* strain MUSC 273<sup>T</sup>, novel alpha-proteobacterium isolated from intertidal soil. *Prog Microbes Mol Biol* 2018; 1(1).
61. Letchumanan V, Ser H-L, Chan K-G, *et al.*, Genome sequence of *Vibrio parahaemolyticus* VP103 strain isolated from shrimp in Malaysia. *Front Microbiol* 2016; 7: 1496.
62. Chan K-G and Tan W-S, Insights into *Cedecea neteri* strain M006 through complete genome sequence, a rare bacterium from aquatic environment. *Standards in Genomic Sciences* 2017; 12(1): 1-7.
63. Aziz RK, Bartels D, Best AA, *et al.*, The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* 2008; 9(1): 1-15.
64. Overbeek R, Olson R, Pusch GD, *et al.*, The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). *Nucleic Acids Res* 2014; 42(D1): D206-D214.
65. Brettin T, Davis JJ, Disz T, *et al.*, RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. *Sci Rep* 2015; 5(1): 1-6.
66. Tatusova T, DiCuccio M, Badretdin A, *et al.*, NCBI prokaryotic genome annotation pipeline. *Nucleic Acids Res* 2016; 44(14): 6614-6624.
67. Hyatt D, Chen G-L, LoCascio PF, *et al.*, Prodigal: prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* 2010; 11(1): 1-11.
68. Lagesen K, Hallin P, Rødland EA, *et al.*, RNAmmer: consistent and rapid annotation of ribosomal RNA genes. *Nucleic Acids Res* 2007; 35(9): 3100-3108.
69. Lowe TM and Eddy SR, tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. *Nucleic Acids Res* 1997; 25(5): 955-964.
70. Blin K, Shaw S, Steinke K, *et al.*, antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. *Nucleic Acids Res* 2019; 47(W1): W81-W87.
71. Weber T, Blin K, Duddela S, *et al.*, antiSMASH 3.0—a comprehensive resource for the genome mining of biosynthetic gene clusters. *Nucleic Acids Res* 2015; 43(W1): W237-W243.
72. Blin K, Wolf T, Chevrette MG, *et al.*, antiSMASH 4.0—improvements in chemistry prediction and gene cluster boundary identification. *Nucleic Acids Res* 2017; 45(W1): W36-W41.
73. Medema MH, Blin K, Cimermancic P, *et al.*, antiSMASH: rapid identification, annotation and analysis of secondary metabolite biosynthesis gene clusters in bacterial and fungal genome sequences. *Nucleic Acids Res* 2011; 39(suppl\_2): W339-W346.
74. Blin K, Medema MH, Kazempour D, *et al.*, antiSMASH 2.0—a versatile platform for genome mining of secondary metabolite producers. *Nucleic Acids Res* 2013; 41(W1): W204-W212.

75. Kjaerulff L, Sikandar A, Zaburannyi N, *et al.*, Thioholgamides: Thioamide-containing cytotoxic RiPP natural products. *ACS Chem Biol* 2017; 12(11): 2837-2841.
76. Ser H-L, Palanisamy UD, Yin W-F, *et al.*, *Streptomyces malaysiense* sp. nov.: a novel Malaysian mangrove soil actinobacterium with antioxidative activity and cytotoxic potential against human cancer cell lines. *Sci Rep* 2016; 6(1): 1-12.
77. Dahlem C, Siow WX, Lopatniuk M, *et al.*, Thioholgamide A, a new anti-proliferative anti-tumor agent, modulates macrophage polarization and metabolism. *Cancers (Basel)* 2020; 12(5): 1288.
78. Ab Mutalib N-S, Wong SH, Ser H-L, *et al.*, Bioprospecting of microbes for valuable compounds to mankind. *Prog Microbes Mol Biol* 2020; 3(1).
79. Zotchev SB, Sekurova ON, and Katz L, Genome-based bioprospecting of microbes for new therapeutics. *Curr Opin Biotechnol* 2012; 23(6): 941-947.
80. Cabello LO, *Microorganisms as Alternative Sources of New Natural Products*, in *Natural products-From bioactive molecules to human health*. 2020, IntechOpen.
81. Liu Z, Zhao Y, Huang C, *et al.*, Recent advances in silent gene cluster activation in *Streptomyces*. *Frontiers in Bioengineering and Biotechnology* 2021; 9.
82. Csolleiova D, Knirschova R, Rezuchova B, *et al.*, An efficient system for stable markerless integration of large biosynthetic gene clusters into *Streptomyces* chromosomes. *Appl Microbiol Biotechnol* 2021; 105(5): 2123-2137.
83. Kang H-S and Kim E-S, Recent advances in heterologous expression of natural product biosynthetic gene clusters in *Streptomyces* hosts. *Curr Opin Biotechnol* 2021; 69: 118-127.
84. Liu S, Wang M, Du G, *et al.*, Improving the active expression of transglutaminase in *Streptomyces lividans* by promoter engineering and codon optimization. *BMC Biotechnol* 2016; 16(1): 1-9.
85. Komatsu M, Uchiyama T, Ōmura S, *et al.*, Genome-minimized *Streptomyces* host for the heterologous expression of secondary metabolism. *Proc Natl Acad Sci* 2010; 107(6): 2646-2651.



Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:

Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.